Morphic Holding, Inc.(MORF) Stock Research - Grey Stern Research

Morphic Holding, Inc. (MORF) Stock Analysis

$56.99 (0.04%)

MORF Financial Performance


Use the table below to view Morphic Holding, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $56.99 -
52 Week Low $19.35 -
52 Week High $57.00 -
Market Cap $2.9 Billion 7/16
Gross Margin 0% 7/16
Profit Margin 0% 2/16
EBITDA margin -100% 2/16
Q2 - 2024 Revenue $0 7/16
Q2 - 2024 Earnings -$57.6 Million 10/16
Q2 - 2024 Free Cash Flow -$32.4 Million 10/16
Trailing 4 Quarters Revenue $60.2 Million 16/16
Trailing 4 Quarters Earnings -$179.8 Million 10/16
Quarterly Earnings Growth -315% 15/16
Annual Earnings Growth -120% 16/16
Quarterly Revenue Growth -100% 15/16
Annual Revenue Growth -197% 16/16
Cash On Hand $50.8 Million 14/16
Short Term Debt $2.2 Million 8/16
Long Term Debt $1.2 Million 14/16

Morphic Holding, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Morphic Holding, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 2/16
PS -47.52 16/16
PB 4.63 4/16
PC 56.38 2/16
Liabilities to Equity 0.04 13/16
ROA -0.28 9/16
ROE -0.29 9/16
Current Ratio 23.36 4/16
Quick Ratio 22.72 3/16
Long Term Debt to Equity 0.00 12/16
Debt to Equity 0.01 9/16
Burn Rate 0.87 15/16
Cash to Cap 0.02 15/16
CCR 0.56 14/16
EV to EBITDA -43.33 12/16
EV to Revenue -46.73 16/16

Company Details

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CEO: DR. Praveen Tipirneni

Website: https://www.morphictx.com

Address: 35 Gatehouse Dr # A2 Waltham, MASSACHUSETTS

Exchange: NASDAQ Global Market

Industry: Biotechnology

Morphic Holding, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Morphic Holding, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Viking Therapeutics, Inc. VKTX $3.9 Billion
Madrigal Pharmaceuticals, Inc. MDGL $6.0 Billion
Protagonist Therapeutics, Inc. PTGX $2.3 Billion
Stoke Therapeutics, Inc. STOK $502.7 Million
Revolution Medicines, Inc. RVMD $7.3 Billion
89bio, Inc. ETNB $737.2 Million
Pliant Therapeutics, Inc. PLRX $768.6 Million
Vaxcyte, Inc. PCVX $11.1 Billion
Avidity Biosciences, Inc. RNA $3.3 Billion
Inozyme Pharma, Inc. INZY $88.7 Million
Terns Pharmaceuticals, Inc. TERN $393.3 Million
DICE Therapeutics, Inc. DICE $2.3 Billion
Immunocore Holdings plc IMCR $1.5 Billion
Arcellx, Inc. ACLX $3.7 Billion
Ventyx Biosciences, Inc. VTYX $138.6 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement

Latest News

MORF Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 0 -$57.6 Million
Q1 2024 $ 0 -$45.3 Million
Q4 2023 $ 60.2 Million -$40.7 Million
Q3 2023 $ 0 -$36.2 Million
Q2 2023 $ 60.2 Million $26.8 Million
Q1 2023 $ 521,000 -$36.1 Million
Q4 2022 $ 6.1 Million -$24.4 Million
Q3 2022 $ 2.1 Million -$30.0 Million

View All

MORF Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $50.8 Million $646.1 Million $3.3 Million $618.4 Million
Q1 2024 $44.4 Million $682.8 Million $3.3 Million $663.6 Million
Q4 2023 $58.6 Million $722.5 Million $2.3 Million $697.0 Million
Q3 2023 $74.2 Million $743.6 Million $1.1 Million $723.2 Million
Q2 2023 $217.3 Million $748.7 Million $1.6 Million $729.4 Million
Q1 2023 $41.9 Million $441.9 Million $3.5 Million $426.5 Million
Q4 2022 $59.3 Million $368.6 Million $3.8 Million $349.1 Million
Q3 2022 $85.0 Million $389.2 Million $2.7 Million $365.1 Million

View All

MORF Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 -$32.4 Million -$275,000 $6.4 Million
Q1 2024 -$47.1 Million -$674,000 -$14.2 Million
Q4 2023 -$28.7 Million -$93,000 -$15.7 Million
Q3 2023 -$36.2 Million $0 -$36.2 Million
Q2 2023 $0 $0 $0
Q1 2023 -$32.0 Million -$550,000 -$17.4 Million
Q4 2022 -$25.2 Million -$64,000 -$25.7 Million
Q3 2022 -$25.1 Million -$249,000 -$56.2 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions